I-Mab Investor Relations Material
Latest events
Status Update
I-Mab
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from I-Mab
Access all reports
I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of innovative biologics, particularly in the fields of immuno-oncology and immuno-inflammation. The company has a diverse pipeline, including several antibody-based therapies aimed at treating various forms of cancer. These include drugs in different phases of clinical trials, such as Uliledlimab for solid tumors and Lemzoparlimab for hematologic malignancies. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.
Key slides for I-Mab
Q3 2024
I-Mab
Corporate Presentation
I-Mab
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
IMAB
Country
🇺🇸 United States